Stay updated on Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.5.4 has been added and Revision: v3.5.3 has been removed, indicating a small update to the page's revision metadata. This is a routine maintenance change and does not alter the study details or other substantive content on the page.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page’s footer software/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a non-content site update.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page's revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check77 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2. This appears to be a minor version update with no visible changes to study content.SummaryDifference0.0%

- Check98 days agoChange DetectedFallopian tube cancer was added to the conditions list and Genetic and Rare Diseases Information Center resources were added. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

Stay in the know with updates to Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.